Sinexus gets $20M, Entellus takes $15M for sinus products
Feeling stuffy? Two sinus-focused companies, Palo Alto, Calif.-based Sinexus and Maple Grove, Minn.-based Entellus, want to help out, with fresh rounds of funding for product development.
Venture funding for ear, nose & throat (ENT) companies hasn’t been terribly common in the past, but seems to be on the rise, with companies like these two and Acclarent, which took $35 million last year, promising safer, easier treatments for common sinus conditions. Acclarent just filed for an $86.25… Continue Reading
Life sciences briefing: Friday, Sept. 28, 2007
Featured companies: Imalux, Sagent Pharmaceuticals, Sequel Pharmaceuticals, Sinexus, TranS1, U.S. Spinal Technologies
Sagent Pharmaceuticals draws in $53M for injectable generics — Sagent Pharmaceuticals, proving that there’s still life in the apparently lucrative but boring specialty-pharmaceuticals business, raised $53 million in a first funding round. Vivo Ventures led the round for the Schaumburg, Ill., company.
Like other specialty pharmas, Sagent essentially picks up abandoned or cast-off drugs from other companies and tries to make them work in new ways…. Continue Reading